Salter Brian, Cooper Melinda, Dickins Amanda
Institute of Health, Global Biopolitics Research Group, University of East Anglia, Norwich, UK.
Regen Med. 2006 Sep;1(5):671-83. doi: 10.2217/17460751.1.5.671.
There is a growing consensus, amongst policy analysts and scientists alike, that China is likely to play a key role in the scientific, clinical and commercial development of stem cell research. However, to date, there exist few detailed analyses of China's current investment in the field. After introducing the UK's recent political strategy on stem cell science, this article develops an in-depth discussion of the formal organization of China's research and development in the area, as well as its rapidly evolving commercial, regulatory and ethical environment. From here, we go on to assess the probability of China's emergence as a global player in the increasingly internationalized business of stem cell biomedicine.
政策分析师和科学家们越来越达成共识,即中国很可能在干细胞研究的科学、临床和商业发展中发挥关键作用。然而,迄今为止,对中国目前在该领域的投资鲜有详细分析。在介绍了英国近期关于干细胞科学的政治战略后,本文深入探讨了中国在该领域研发的正式组织情况,以及其迅速演变的商业、监管和伦理环境。在此基础上,我们进而评估中国在日益国际化的干细胞生物医学业务中成为全球参与者的可能性。